Повышение качества жизни мужчин с симптомами нижних мочевых путей при применении везомни в рутинной клинической практике в Европе

Повышение качества жизни мужчин с симптомами нижних мочевых путей при применении везомни в рутинной клинической практике в Европе

Автор: Rees J., Foley S., Huang M., Arias J.R., Skoumal R., Walters C., Yavuz Y., De Wachter S.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Андрология

Статья в выпуске: 3, 2019 года.

Бесплатный доступ

Цель. Оценить влияние лекарственного средства Везомни (Vesomni™/Urizia™/Volutsa™) - комбинированного препарата в форме таблеток с фиксированной дозировкой, содержащего 6мг солифенацина (М-холинолитика) и 0,4 мг тамсулозина (а-адреноблокатора), на связанное со здоровьем качество жизни (СЗКЖ) и удовлетворенность лечением у мужчин с симптомами нижних мочевых путей (СНМП), обусловленными доброкачественной гиперплазией предстательной железы (ДГПЖ), при применении его в рутинной клинической практике. Методы. Исследование EUROPA - это неинтервенционное исследование группы мужчин с СНМП/ДГПЖ, у которых не наблюдалось эффекта от монотерапии и которые в рамках обычной клинической практики получали препарат Везомни. Данные исследования собирали ретроспективно (1 год) и проспективно (1 год). Выполняли анализ данных на исходном уровне, на 4-8 неделях, на 9-18 неделях (факультативно), на 19-39й неделях (факультативно) и на 40-52 неделях. Первичной конечной точкой было изменение от исходного уровня показателя СЗКЖ при оценке по шкале обеспокоенности симптомами Опросника для оценки гиперактивного мочевого пузыря (OAB-q)...

Еще

Доброкачественная гиперплазия предстательной железы, исследование europa, симптомы нижних мочевых путей, мужчина, качество жизни, удовлетворенность лечением, везомни

Короткий адрес: https://sciup.org/142223147

IDR: 142223147   |   DOI: 10.29188/2222-8543-2019-11-3-134-143

Список литературы Повышение качества жизни мужчин с симптомами нижних мочевых путей при применении везомни в рутинной клинической практике в Европе

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. DOI: 10.1067/mob.2002.125704
  • Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep 2017;7:7984. DOI: 10.1038/s41598-017-06628-8
  • Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009;103 Suppl 3:12-23. DOI: 10.1111/j.1464-410X.2009.08369.x
  • Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Ci Ji YiXueZaZhi 2017;29:79-83. DOI: 10.4103/tcmj.tcmj_20_17
  • Cindolo L, Pirozzi L, Sountoulides P, Fanizza C, Romero M, Castellan P, et al. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associ-ated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol 2015;15:96. DOI: 10.1186/s12894-015-0090-x
  • Hakimi Z, Johnson M, Nazir J, Blak B, Odeyemi IA. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Curr Med Res Opin 2015;31:43-50.
  • DOI: 10.1185/03007995.2014.968704
  • Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational surveyof the aging male (MSAM-7). Eur Urol 2003;44:637-649.
  • DOI: 10.1016/j.eururo.2003.08.015
  • European Association of Urology. Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatis Obstruction (BPO). Available at: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTSGuidelines-2015-v2.pdf. Accessed May 8, 2018.
  • Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
  • DOI: 10.1016/j.eururo.2013.03.004
  • Lee HN, Lee KS, Kim JC, Chung BH, Kim CS, Lee JG, et al. Rate and associated factors of solifenacin add-on afterr tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Int J Clin Pract 2015;69:444-453.
  • DOI: 10.1111/ijcp.12581
  • VesomniTM/UriziaTM/VolutsaTM. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/28535/. Accessed 23 April, 2018.
  • van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013;64:1003-1012.
  • DOI: 10.1016/j.eururo.2013.07.034
  • Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol 2015;67:262-270.
  • DOI: 10.1016/j.eururo.2014.07.013
  • Drake MJ, Bowditch S, Arbe E, Hakimi Z, Guelfucci F, Amri I, et al. A retrospective study of treatment persistence and adherence to alpha-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol 2017;17:36.
  • DOI: 10.1186/s12894-017-0226-2
  • Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-574.
  • Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol 1992;148:1549-63
  • DOI: 10.1016/s0022-5347(17)36967-7
  • EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
  • Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176:627-632; discussion 632. di:
  • DOI: 10.1016/j.juro.2006.03.088
  • Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-1774. 10.1016/s0022-53 47(01)66780-6
  • DOI: 10.1016/s0022-5347(01)66780-6
  • Speakman M, Kirby R, D oyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int 2015;115:508-519.
  • DOI: 10.1111/bju.12745
  • Drake MJ, Sokol R, Coyne K, Hakimi Z, Nazir J, Dorey J, et al. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU Int 2016;117:165-172. 10.1111 /bju.13162
  • DOI: 10.1111/bju.13162
  • Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 2012;109:1831-1840.
  • DOI: 10.1111/j.1464-410X.2011.10624.x
  • Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol 2013;64:398-407.
  • DOI: 10.1016/j.eururo.2013.03.031
  • Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-1774.
  • DOI: 10.1111/j.1464-410X.2012.11023.x
  • Drake MJ, Oelke M, Snijder R, Klaver M, Traudtner K, van Charldorp K, et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin tamsulosin OCAS for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One 2017;12:e0170726
  • DOI: 10.1371/journal.pone.0170726
Еще
Статья научная
SciUp 2024 © 2024 ©